Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3468-3474

  Jeremiah, Kidola ^a,b   Denti, Paolo ^c   Chigutsa, Emmanuel ^c   Faurholt Jepsen, Daniel ^d   PrayGod, George ^b   Range, Nyagosya ^b   Castel, Sandra ^c   Wiesner, Lubbe ^c   Hagen, Christian Munch ^e   Christiansen, Michael ^e   Changalucha, John ^b   McIlleron, Helen ^c   Friis, Henrik ^d   Andersen, Aase Bengaard ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MINERAL; PYRAZINAMIDE; RIFAMPICIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; VITAMIN;

ADULT; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MIXED INFECTION; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS; BIOAVAILABILITY; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DIETARY SUPPLEMENT; DRUG EFFECTS; FEMALE; HIV INFECTIONS; MALE; MIDDLE AGED; WEIGHT GAIN;

ADULT; BIOLOGICAL AVAILABILITY; BODY MASS INDEX; BODY WEIGHT; COHORT STUDIES; COINFECTION; DIETARY SUPPLEMENTS; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; TUBERCULOSIS; WEIGHT GAIN;

EID: 84901271734     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02307-13     Document Type: Article

References (39)

1. Raviglione M, Marais B, Floyd K, Lonnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SH, Zumla A. 2012. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379:1902-1913. http://dx.doi.org/10.1016/S0140-6736(12)60727-2.
2. Van Lettow M, Fawzi WW, Semba RD. 2003. Triple trouble: the role of malnutrition in tuberculosis and human immunodeficiency virus coinfection. Nutr. Rev. 61:81-90. http://dx.doi.org/10.1301/nr.2003.marr.81-90.
3. World Health Organization. 2011. Global HIV/AIDS response epidemic update and health sector progress towards universal access: progress report 2011. World Health Organization, Geneva, Switzerland.
4. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland.
5. World Health Organization. 2010. Multidrug and extensively drugresistant TB (M/XDR-TB) 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland.
6. Ministry of Health and Social Welfare. 2006. Manual of the national tuberculosis and leprosy programme in Tanzania, 5th ed. Ministry of Health and Social Welfare, Dar es Salaam, Tanzania.
7. Pasipanodya JG, Srivastava S, Gumbo T. 2012. Meta-Analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. 55:169-177. http://dx.doi.org/10.1093/cid/cis353.
8. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177. http://dx.doi.org/10.1128/AAC.50.4.1170-1177.2006.
9. Polasa K, Murthy KJ, Krishnaswamy K. 1984. Rifampicin kinetics in undernutrition. Br. J. Clin. Pharmacol. 17:481-484. http://dx.doi.org/10.1111/j. 1365-2125.1984.tb02377.x.
10. Onwubalili JK. 1988. Malnutrition among tuberculosis patients in Harrow, England. Eur. J. Clin. Nutr. 42:363-366.
11. Range NS, Malenganisho W, Temu MM, Changalucha J, Magnussen P, Krarup H, Andersen AB, Friis H. 2010. Body composition of HIVpositive patients with pulmonary tuberculosis: a cross-sectional study in Mwanza, Tanzania. Ann. Trop. Med. Parasitol. 104:81-90. http://dx.doi.org/10.1179/136485910X12607012373830.
12. Range N, Andersen AB, Magnussen P, Mugomela A, Friis H. 2005. The effect of micronutrient supplementation on treatment outcome in patients with pulmonary tuberculosis: a randomized controlled trial in Mwanza, Tanzania. Trop. Med. Int. Health 10:826-832. http://dx.doi.org/10.1111/j.1365-3156.2005.01463.x.
13. Range N, Changalucha J, Krarup H, Magnussen P, Andersen AB, Friis H. 2006. The effect of multi-vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza, Tanzania. Br. J. Nutr. 95:762-770. http://dx.doi.org/10.1079/ BJN20051684.
14. Academy of Science of South Africa. 2007. HIV/AIDS, TB and nutrition: scientific inquiry into the nutritional influences on human immunity with special reference to HIV infection and active TB in South Africa. Academy of Science of South Africa, Pretoria, South Africa.
15. PrayGod G, Range N, Faurholt-Jepsen D, Jeremiah K, Faurholt-Jepsen M, Aabye MG, Jensen L, Jensen AV, Grewal HM, Magnussen P, Changalucha J, Andersen AB, Friis H. 2011. Daily multi-micronutrient supplementation during tuberculosis treatment increases weight and grip strength among HIV-uninfected but not HIV-infected patients in Mwanza, Tanzania. J. Nutr. 141:685-691. http://dx.doi.org/10.3945/jn.110.131672.
16. Frisancho AR. 1990. Anthropometric standards for the assessment of growth and nutritional status. University of Michigan Press, Ann Arbor, MI.
17. Beal S, Sheiner L, Boeckmann A, Bauer R. 2009. NONMEM users guides (1989-2009). ICON Development Solutions, Ellicott City, MD.
18. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob. Agents Chemother. 52:2138-2148. http://dx.doi.org/10.1128/AAC.00461-07.
19. Savic RM, Karlsson MO. 2009. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 11:558-569. http://dx.doi.org/10.1208/s12248-009-9133-0.
20. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094708.
21. Denti P, Smythe W, Simonsson US, Rustomjee R, Onyebujoh P, Smith P, McIlleron H. 2010. A population pharmacokinetic model for rifampicin auto-induction, abstr 12. Proc. 3rd Int. Workshop Clin. Pharmacol. TB Drugs, Boston, MA.
22. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504. http://dx.doi.org/10.1023/A:1012299115260.
23. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151. http://dx.doi.org/10.1208/s12248-011- 9255-z.
24. Karyadi E, West CE, Schultink W, Nelwan RH, Gross R, Amin Z, Dolmans WM, Schlebusch H, van der Meer JW. 2002. A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. Am. J. Clin. Nutr. 75:720-727.
25. Ramakrishnan CV, Rajendran K, Jacob PG, Fox W, Radhakrishna S. 1961. The role of diet in the treatment of pulmonary tuberculosis. An evaluation in a controlled chemotherapy study in home and sanatorium patients in South India. Bull. World Health Organ. 25:339-359.
26. Gupta KB, Gupta R, Atreja A, Verma M, Vishvkarma S. 2009. Tuberculosis and nutrition. Lung India 26:9-16. http://dx.doi.org/10.4103/0970-2113.45198.
27. Delezay O, Yahi N, Tamalet C, Baghdiguian S, Boudier JA, Fantini J. 1997. Direct effect of type 1 human immunodeficiency virus (HIV-1) on intestinal epithelial cell differentiation: relationship to HIV-1 enteropathy. Virology 238:231-242. http://dx.doi.org/10.1006/viro.1997.8829.
28. Facanha MC, Gondim AM, Pinheiro VG, Barroso EC, Peloquin CA, Guerrant RL, Lima AA. 2009. Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis. Braz. J. Infect. Dis. 13:210-217. http://dx.doi.org/10.1590/S1413- 86702009000300011.
29. Pinheiro VG, Ramos LM, Monteiro HS, Barroso EC, Bushen OY, Facanha MC, Peloquin CA, Guerrant RL, Lima AA. 2006. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz. J. Infect. Dis. 10:374-379. http://dx.doi.org/10.1590/S1413-86702006000600003.
30. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Venkatesan P, Sekar L, Kumar S, Krishnarajasekhar OR, Paramesh P. 2004. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin. Infect. Dis. 38:280-283. http://dx.doi.org/10.1086/380795.
31. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Padmapriyadarsini C, Swaminathan S, Bhagavathy S, Venkatesan P, Sekar L, Mahilmaran A, Ravichandran N, Paramesh P. 2004. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48:4473-4475. http://dx.doi.org/10.1128/AAC.48.11.4473-4475.2004.
32. Semba RD. 1998. The role of vitamin A and related retinoids in immune function. Nutr. Rev. 56:38-48.
33. Zachariah R, Spielmann MP, Harries AD, Salaniponi FM. 2002. Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. Trans. R. Soc. Trop. Med. Hyg. 96:291-294. http://dx.doi.org/10.1016/S0035-9203(02)90103-3.
34. Macallan DC, McNurlan MA, Kurpad AV, de Souza G, Shetty PS, Calder AG, Griffin GE. 1998. Whole body protein metabolism in human pulmonary tuberculosis and undernutrition: evidence for anabolic block in tuberculosis. Clin. Sci. (Lond.) 94:321-331.
35. McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C, Rida W, Pym A, Smith PJ, Onyebujoh PC. 2012. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob. Agents Chemother. 56:3232-3238. http://dx.doi.org/10.1128/AAC.05526-11.
36. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. 2013. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 208:1464-1473. http://dx.doi.org/10.1093/infdis/jit352.
37. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H. 2011. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob. Agents Chemother. 55:4122-4127. http://dx.doi.org/10.1128/AAC.01833-10.
38. Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, Mac Kenzie WR, Bliven-Sizemore E, Johnson JL, Vernon A. 2010. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54:4192-4200. http://dx.doi.org/10.1128/AAC.00353- 10.
39. He YJ, Zhang W, Chen Y, Guo D, Tu JH, Xu LY, Tan ZR, Chen BL, Li Z, Zhou G, Yu BN, Kirchheiner J, Zhou HH. 2009. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T-C polymorphism. Clin. Chim. Acta 405:49-52. http://dx.doi.org/10.1016/j.cca.2009.04.003.